

1	Introduction	1
	Measuring Health and Disease	2
	Is There a Better Definition of Health?	5
	Determinants of Health	6
	Maintaining Health	6
	Observations of Daily Living	6
	Social Activity	6
	Hygiene	7
	Stress Management	7
	Health Care	7
	Workplace Wellness Programs	7
	Public Health	8
	Role of Science in Health	9
	Applied Health Sciences	9
2	Health and Disease as Two Sides of the Same Coin	11
	Low-Grade Systemic Inflammation Occurs in Many Diseases	11
3	Inflammation	15
	Introduction	15
	Phases of Inflammatory Response	16
	Components of Acute Inflammation	17
	Vascular Changes	18
	Cellular Events	23
	Mediators of Inflammation	34
	Histamine	35
	Serotonin	37
	Effects of Food Content	40
	Location of Serotonergic Neurons	42
	5-HT Receptors	42
	Serotonylation	43
	Biosynthesis of Serotonin	43

Drugs Targeting the 5-HT System	43
Serotonin Modulates Inflammation and Immune Response	44
Dopamine	45
Catecholamines	46
Acetylcholine	48
Melanocortin	48
Leptin	49
Neuropeptide Y	50
Ghrelin	51
Gut Peptides	53
Cholecystokinin	54
Kinins	56
Essential Fatty Acids and Their Products	58
Cyclo-oxygenase (COX), Lipoxygenase (LO) Pathways and Generation of Lipoxins, Resolvins, Protectins and Maresins	59
Aspirin-triggered 15 Epimer LXs (ATLs) and Resolvins and Formation of Protectins and Maresins	62
Platelet Activating Factor (PAF)	63
Cytokines in Inflammation	65
Chemokines in Inflammation	66
Nitric Oxide (NO)	67
NO is an Endogenous Anti-infective Molecule	69
NO and Cellular Senescence	70
NO and Brain-derived Neurotrophic Factor (BDNF)	71
Leukocyte Lysosomal Enzymes	72
Reactive Oxygen Species (ROS)	73
Neuropeptides in Inflammation	74
Obesity, type 2 diabetes, hypertension, hyperlipidemia, insulin resistance, Alzheimer's disease, depression, schizophrenia and cancer are low-grade systemic inflammatory conditions	74
Diagnosis of Low-grade Systemic Inflammation	76
Hs-CRP	76
Cytokines and Chemokines	77
Conventional Markers of Inflammation	78
Role of Pro-inflammatory Markers in the Pathophysiology of the Low-grade Systemic Inflammatory Conditions	78
4 Essential Fatty Acids—Biochemistry, Physiology and Clinical Significance	101
Introduction	101
Metabolism of EFAs	102
The n-6 Polyunsaturated Fatty Acids	102
The n-3 Polyunsaturated Fatty Acids	105
Dietary Sources of EFAs	109

The Activities of Δ^6 and Δ^5 Desaturases Are Low in Humans	110
Modulators of EFAs/PUFAs Metabolism	111
Protein and Insulin Augment Δ^6 Desaturase Activity	111
Ageing and Season Influence Δ^6 Desaturase Activity	112
Oncogenic Viruses, Radiation, SREBP and PPARs Influence	
EFA Metabolism	112
Statins Enhance EFA Metabolism	113
Trans-fats, Saturated Fats and Cholesterol Inhibit	
Δ^6 Desaturase	113
Zinc Modifies EFA and PG Metabolism	114
Magnesium is an Essential Co-factor for Normal Δ^6 Desaturase ...	115
Calcium Enhances PGI ₂ Synthesis and Interacts with PUFAs	116
Vitamin C and Ethanol Enhance the Formation of PGE ₁	117
Actions of EFAs/PUFAs and Their Metabolites	117
Cell Membrane Fluidity	117
EFAs/PUFAs Have Second Messenger Actions	119
PUFAs Behave as Endogenous Anti-infective Molecules	120
PUFAs Inhibit ACE Activity and Enhance Endothelial	
Nitric Oxide Generation	122
PUFAs and Cytokines	124
PUFAs Decrease HMG-CoA Reductase Activity	126
Lipoxins, Resolvins, Protectins and Maresins	127
NO Reacts with PUFAs to Yield Nitrolipids	129
Formation of Nitro Fatty Acids (Nitrolipids) in Tissues	134
Actions of Nitro Fatty Acids (Nitrolipids)	136
Interaction(s) Among n-3, n-6 Fatty Acids, NO and Nitrolipids	138
5 Cell Membrane Organization	153
Introduction	153
Fluid Mosaic Model of the Membrane	153
The Phospholipid (PL) Bilayer—Its Structure, Properties	
and Functions	154
Cell Membrane Properties	158
Integral Membrane Proteins	159
Cell Membrane-Cytoskeleton Integration	159
Cell Membrane Lipids	160
Plasma Membrane Carbohydrates	161
Plasma Membrane Proteins	161
Cell Membrane Permeability	162
Lipid Rafts, Caveolae and Polyunsaturated Fatty Acids (PUFAs) ...	166
6 Low-grade Systemic Inflammation is Present in Common	
Diseases/Disorders	175
Introduction	175
Low-grade Systemic Inflammation is Present in Chronic	
Diseases	177

7 Obesity	181
Definition of Obesity	182
Incidence and Prevalence of Obesity	182
Obesity May Be Familial	183
Fast Food Industry and Obesity	183
Obesity Is Harmful	184
Genetic and Non-genetic Factors Contributing to Obesity	185
Gene Expression Profile in Obesity	186
All Adipose Cells are Not the Same	187
Biochemical and Functional Differences Between Adipose Cells of Different Regions	188
Intramyocellular Lipid (IMCL) Droplets and Perilipins	189
Perilipins and Inflammation	189
Low Grade Systemic Inflammation Occurs in Obesity	190
Weight Loss Ameliorates Inflammation	192
Adipose Tissue Macrophages (ATMs) and Inflammation	193
Macrophage Differentiation Is Dependent on Fatty Acid Synthesis	194
Fatty Acid Metabolism Enhances T Cell Memory	195
What Causes Abdominal Obesity—How and Why?	198
Excess 11β -hydroxysteroid Dehydrogenase Type 1 (11β -HSD-1) Enzyme Activity May Cause Abdominal Obesity	198
Interaction Among 11β -HSD-1, TNF- α and Insulin	199
Glucocorticoids and Perilipins	201
Glucocorticoids, TNF- α , and Inflammation	202
Diet, Genetics, Inflammation and Obesity	203
Gut and Obesity	205
Perinatal Nutritional Environment Influences Development of Obesity	206
Obesity and Type 2 Diabetes Mellitus as Disorders of the Brain	206
Cross-Talk Between the Liver, Adipose Tissue and the Brain Through Vagus	207
Cross-Talk Between the Liver and Pancreatic β Cells is Mediated by the Vagus	207
The Gut-Brain-Liver Axis Circuit is Activated by Long-Chain Fatty Acids	208
BDNF and Obesity	211
Interaction(s) Among Insulin, Melanocortin, and BDNF	212
Ghrelin, Leptin, and BDNF	213
Obesity and Type 2 Diabetes Mellitus Are Inflammatory Conditions	213
BDNF and Inflammation	214
Gut Bacteria and Obesity	215
Gut Flora	215
Gut Bacteria Are Different in the Lean and Obese	216
Gut Bacteria and GPR41	217

Diet, Low-Grade Systemic Inflammation, and Obesity	219
Gastric Bypass Surgery for Obesity Alters Gut Bacteria and Hypothalamic Factors	219
Insulin Acts Not only on Peripheral Tissues but Also in the Brain	220
Interaction Between PUFAs and BDNF and its Relationship to Obesity ..	221
Diet, Gut Peptides and Hypothalamic Neurotransmitters in Obesity	221
8 Hypertension	239
Introduction	239
Nutritional Factors in the Pathobiology of HTN	240
Interaction(s) Between Minerals, Trace Elements, Vitamins and Essential Fatty Acids	241
Salt, Calcium, NO, and Hypertension	242
Asymmetrical Dimethylarginine and Hypertension	243
NO, ADMA and Oxidative Stress in Preeclampsia	243
VEGF, Endoglin, Placental Growth Factor, TGF- β , Catechol-O-methyltransferase Activity and Preeclampsia	246
Homocysteine and Endothelial Damage	248
Nutritional Factors, Oxidant Stress and Endothelial Dysfunction	249
Increased Oxidant Stress Occurs in Hypertension	250
Superoxide Anion Production Is Increased in Hypertension: How and Why?	251
Superoxide Anion and Hypertension	252
NO and Hypertension	252
Cyclosporine Increases Blood Pressure by Augmenting O_2^- Generation	253
Anti-hypertensive Drugs Enhance eNO Synthesis and Show Antioxidant Property	253
Transforming Growth Factor- β (TGF- β) in Hypertension	255
Essential Fatty Acids and Blood Pressure	256
Free Radicals, NO, ACE Activity and Essential Hypertension	257
Essential Fatty Acids and Hypertension	259
Low-grade Systemic Inflammation Occurs in Hypertension	262
Does Adult Hypertension have its Origins in the Perinatal Period?	262
9 Insulin Resistance, Dyslipidemia, Type 2 Diabetes Mellitus and Metabolic Syndrome	277
Introduction	277
Metabolic Syndrome	278
Metabolic Syndrome Is an Inflammatory Condition	279
Why Abdominal Obesity Occurs?	279
Glucose Is Pro-inflammatory in Nature	280
Insulin Is Anti-inflammatory in Nature	281

Endothelial Nitric Oxide in Metabolic Syndrome	281
Perinatal Origins of Metabolic Syndrome	284
Hypothalamic Neuropeptides and Food Intake	286
Appetite Regulatory Centers Are in Place During Perinatal Period and Fine-tuned/Programmed by Maternal and Perinatal Factors	286
Ventromedial Hypothalamus may have a Role in the Development of Type 2 Diabetes Mellitus	288
Insulin Receptors in the Brain and the Metabolic Syndrome	290
Mechanism of Action of Insulin Receptors in the Brain and Elsewhere	291
Insulin, GLUT-4 and Glucose Transport	297
Muscle-specific GLUT-4 Knockout Mice (MG4KO)	297
Fat-specific GLUT-4 Knockout Mice	299
PUFAs, Expression of Insulin Receptors and GLUTs and Diabetes Mellitus	300
Polygenic Knockout Models	302
Triple Heterozygous Knockouts (IR/IRS-1/p85)	302
Weight Loss After Gastric Bypass and Changes in Hypothalamic Neuropeptides and Monoamines	304
Monoaminergic Amines and Hypothalamic and Gut Peptides and Inflammation	305
Dopamine	305
Serotonin (5-hydroxytryptamine)	306
Neuropeptide Y	307
Ghrelin	308
Melanocortin	310
Acetylcholine	311
Adrenaline and Noradrenaline	311
Gut Peptides	312
Leptin	313
Cholecystokinin	314
Neurotransmitters and Gut Peptides as Modulators of Inflammation and Immune Response	315
10 Atherosclerosis	333
Introduction	333
Atherosclerosis Is a Low-grade Systemic Inflammatory Condition	334
Mediators of Inflammation in Atherosclerosis	335
Cross Talk Among Platelets, Leukocytes and Endothelial Cells	337
Lipoxins in Rheumatoid Arthritis	338
Leukocytes and Atherosclerosis	340
Uncoupling Protein-1, Essential Fatty Acids, and Atherosclerosis	341

PUFAs of ω -3 and ω -6 Series, Trans-fats, Saturated Fats, Cholesterol and Their Role in Atherosclerosis	342
Atheroprotective Actions of ω -3 and ω -6 Fatty Acids	343
Effects on Endothelial Function	344
PUFAs Inhibit Angiotensin-converting Enzyme (ACE) Activity and Augment Endothelial Nitric Oxide Generation	345
PUFAs Suppress the Production of Pro-inflammatory Cytokines	346
Effects on HMG-CoA Reductase Enzyme	346
11 Osteoporosis	359
Introduction	359
Dietary Protein and Osteoporosis	359
Magnesium and Osteoporosis	361
Osteoporosis Is a Low-grade Systemic Inflammatory Condition	361
Nitric Oxide in Osteoporosis	364
Post-menopausal Osteoporosis, Cytokines and NO	366
Dose Dependent Action of NO on Bone	366
Anti-diabetic Drug Metformin, NO and Osteoporosis	368
Polyunsaturated Fatty Acids and Osteoporosis	369
12 Alzheimer's Disease, Schizophrenia and Depression	377
Introduction	377
Pathobiology of Alzheimer's Disease	377
Amyloid β in AD	379
Oxidative Stress Causes Neuronal Death	379
Alzheimer's is an Inflammatory Condition	380
Cholinergic System in Alzheimer's Disease	381
Neurotrophic Factors and AD	382
PUFAs in Alzheimer's Disease	384
PUFAs and Neurogenesis and Neurite Outgrowth	385
Interaction(s) Between PUFAs and BDNF	387
Schizophrenia	390
Prenatal and Perinatal Factors on Psychopathology	390
Early Fetal Environment and Development and Schizophrenia	391
Maternal Infections and Schizophrenia	392
Is Schizophrenia an Inflammatory Condition?	393
PUFAs and Their Metabolites and Schizophrenia	393
Depression	395
Depression May Be Associated with Low BDNF Levels	396
BDNF and Serotonin Interact with Each Other	397
BDNF and Inflammation	398
Serotonin and Catecholamines Modulate Inflammation	399
Depression is an Inflammatory Condition	399
Depression and PUFAs	400

13 Rheumatological Conditions	417
Introduction	417
Autoimmunity	418
Self and Non-self and Immunological Tolerance	418
Genetic Factors	419
Gender	420
Environmental Factors	422
Pathogenesis of Autoimmunity	423
Systemic Lupus Erythematosus	427
Pathobiology of Inflammation with Emphasis on Chronic Inflammation	428
Components and Mediators of the Inflammatory Response	429
Cytokines in Inflammation	431
Inflammatory and Anti-inflammatory Molecules and Antioxidants in Lupus	432
TGF- β in Scleroderma and Lupus	434
Immune Dysfunction in Lupus	434
Loss of Self-tolerance in Lupus	435
UV Radiation, Immune Response, Mast Cells and its Role in Lupus	438
Mast Cells in Rheumatological Conditions	439
PLA ₂ , TNF- α , MIF and Pro- and Anti-inflammatory Lipids	440
Glucocorticoids, COX Enzymes, LTs, Cytokines, NO, LXs, and Inflammation	444
Cell Membrane Fatty Acid Content Could Modulate Inflammation and Repair	448
Nitric Oxide, Lipid Peroxides, and Antioxidant Status in Lupus	449
Oxidant Stress, Anti-oxidants, NO and PUFAs in Lupus	450
1,25-dihydroxyvitamin D ₃ Suppresses Autoimmunity	451
ADMA is Useful in Lupus and Other Rheumatological Conditions	452
14 Cancer	465
Tobacco and Cancer	466
Infection and Cancer	466
Tobacco and Inflammation	467
Inflammation of Chronic Infections and Cancer are due to TNF- α and IL-1	468
Glucose Sensing by Neuronal and Tumor Cells and Its Relationship to ATP-Sensitive K ⁺ Channels and ROS	470
Eicosanoids, Free Radicals and Inflammation in Cancer	473
PUFAs, Pro- and Anti-inflammatory Metabolites of PUFAs and Lipid Peroxidation and Cancer	474
Free Radicals Have both Beneficial and Harmful Actions	475
Lipid Peroxidation in Tumor Cells	476

PUFA Deficiency Exists in Tumor Cells	476
Superoxide Dismutase and Free Radicals in Tumor Cells	477
Free Radicals Induce Translocation of p53	478
Oxidant Stress and Telomere	479
Bcl-2 Opposes the Action of p53	479
Polyunsaturated Fatty Acids Inhibit Cell Proliferation by Augmenting Free Radical Generation and Lipid Peroxidation	480
Normal and Tumor Cells May Process PUFAs Differentially	481
15 Aging	491
Introduction	491
Telomere and Aging	492
Theories of Aging	492
Telomere and Aging	493
Telomere in Type 2 Diabetes Mellitus	495
Telomere and Hypertension	497
Endothelial Dysfunction, Insulin Resistance, Obesity, Hypertension, Type 2 Diabetes, Inflammation and Telomere	498
PUFAs and Their Anti-inflammatory Products and Telomere	499
P53, Telomere, Aging, Type 2 Diabetes Mellitus, Cancer	500
Other Theories of Aging	504
Aging is a Low-grade Systemic Inflammatory Condition	504
Exercise is Anti-inflammatory in Nature	506
16 Adult Diseases and Low-Grade Systemic Inflammation Have Their Origins in the Perinatal Period	513
Introduction	513
When and How the Inflammatory Process is Initiated?	515
Perinatal Programming of Adult Diseases	515
Factors Influencing the Metabolism of EFAs	516
PUFAs Modulate Glucose and Glutamine Uptake and Their Metabolism	517
PUFAs, Insulin, and Acetylcholine Function as Endogenous Cyto- and Neuroprotectors	519
PUFAs in Brain Growth and Development	521
Syntaxin, SNARE Complex and PUFAs	521
PUFAs Modulate RAR-RXR and Other Nuclear Receptors and are Essential for Brain Growth and Development	522
PUFAs Modulate Gene Expression and Interact with Cytokine TNF- α and Insulin to Influence Neuronal Growth and Synapse Formation	525
Neurogenesis and Neuronal Movement During the Growth and Development of Brain and PUFAs	527
Insulin, PUFAs and Neuronal Proliferation	528

Catenin, <i>wnt</i> and Hedgehog Signaling Pathway in Brain Growth and Development and PUFAs	529
PUFAs Modulate NMDA, γ -Aminobutyric Acid (GABA), Serotonin and Dopamine in the Brain	532
Maternal Diet Influences EFA Metabolism and Leptin Levels	536
Perinatal PUFA Deficiency May Initiate Low-Grade Systemic Inflammation and Adult Diseases	537
17 Clinical Implications	551
Introduction	551
Glucose-Insulin-Potassium Regimen	552
Ethyl Pyruvate	555
Lipid-enriched Albumin	556
Vagal Nerve Stimulation (VNS) Suppresses Inflammation	558
VNS for Obesity, Hypertension, Type 2 Diabetes Mellitus and Metabolic Syndrome	559
Lipoxins, Resolvins, Protectins or Their Synthetic Analogues	562
Ghrelin	563
PUFAs as Potential Anti-cancer Drugs	563
PUFAs, Especially GLA, for Glioma	565
Modified GLA (and Other PUFAs) for Cancer	566
PUFAs+Growth Factors for Cancer	567
PUFAs for Rheumatological Conditions	568
Index	575